In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

The mitogen-activated protein kinase (MAPK) pathway is essential for cellular proliferation,
growth, and survival. Constitutive activation of this pathway by BRAF mutations can cause …

RAF inhibitors have transformed treatment for BRAF V600-mutant cancer patients, but
clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that …

Advances in tumor molecular profiling have uncovered shared genomic and proteomic
alterations across tumor types that can be exploited therapeutically. A biomarker-driven …

Large-scale tumor molecular profiling has revealed that diverse cancer histologies are
driven by common pathways with unifying biomarkers that can be exploited therapeutically …

Abstract CT033: Safety, pharmacokinetics, and antitumor activity findings from a phase 1b,
open-label, dose-escalation and expansion study investigating RAF dimer inhibitor …

Although rare in non-small cell lung cancer (NSCLC), BRAF mutations present considerable
therapeutic challenges. While the use of BRAF and MEK inhibitor combinations has …

Lung cancer, despite recent advancements in survival rates, represents a significant global
health burden. Non-small cell lung cancer (NSCLC), the most prevalent type, is driven …

RAS mutations occur in approximately 30% of tumors worldwide and have a poor prognosis
due to limited therapies. Covalent targeting of KRAS G12C has achieved significant success …

Abstract Mutated Ras and Raf kinases are well-known to promote cancer metastasis via flux
through the Ras/Raf/MEK/ERK (MAPK) pathway. A role for non-mutated Raf in metastasis is …